Molecular structure of Tadalafil, CAS Number: 171596-29-5
Tadalafil (CAS 171596-29-5)
See product citations (13)
Alternate Names:
(6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1,2:1,6]pyrido[3,4-b]indole-1,4-dione; Cialis; GF 196960; IC 351; ICOS 351; Tildenafil; UK 336017
Application:
Tadalafil is a phosphodiesterase 5 inhibitor
CAS Number:
171596-29-5
Purity:
≥98%
Molecular Weight:
389.40
Molecular Formula:
C22H19N3O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Tadalafil is a potent and selective inhibitor of PDE5A (Phosphodiesterase-5, PDE5). This compound prevents the breakdown of phosphodiesterases, many of which are used as secondary messengers. By preventing the breakdown of these messenger molecules, tadalafil can prolong signal transduction and amplify its effect.
Tadalafil (CAS 171596-29-5) References
- Tadalafil Facilitates the Distal Ureteral Stone Expulsion: A Meta-Analysis. | Bai, Y., et al. 2017. J Endourol. 31: 557-563. PMID: 28384011
- Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. | Gong, B., et al. 2017. Int Urol Nephrol. 49: 1731-1740. PMID: 28741090
- Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. | Sitbon, O., et al. 2020. Eur Respir J. 56: PMID: 32350101
- Solubilization of tadalafil using a tartaric acid and chitosan-based multi-system. | Sohn, JS. and Choi, JS. 2021. Int J Biol Macromol. 168: 866-874. PMID: 33249149
- Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. | Escribano Subías, P., et al. 2021. Expert Rev Respir Med. 15: 493-504. PMID: 33472458
- Comparison of Dapoxetine /Tadalafil and Paroxetine/Tadalafil Combination Therapies for the Treatment of the Premature Ejaculation: A Randomized Clinical Trial. | Mohseni Rad, H., et al. 2021. Urol J. 19: 138-143. PMID: 34773634
- Tadalafil in Increasing Doses: The Influence on Coronary Blood Flow and Oxidative Stress in Isolated Rat Hearts. | Banjac, NM., et al. 2022. Pharmacology. 107: 150-159. PMID: 34903698
- Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma. | Luginbuhl, AJ., et al. 2022. Clin Cancer Res. 28: 915-927. PMID: 34911681
- Maternal blood concentration of tadalafil in pregnancy: Comparison of pregnant and non-pregnant women. | Enomoto, N., et al. 2022. Taiwan J Obstet Gynecol. 61: 230-233. PMID: 35361381
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. | Ruopp, NF. and Cockrill, BA. 2022. JAMA. 327: 1379-1391. PMID: 35412560
- Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms? | Goberdhan, S., et al. 2022. World J Urol. 40: 1799-1803. PMID: 35469100
- Parental exposure of Tadalafil has beneficial effect on reflexive motor behaviors in mice offspring. | Imani, MH., et al. 2022. Int J Dev Neurosci. 82: 397-406. PMID: 35471701
- Tadalafil against hyperoxia-induced oxidative stress; an experimental study. | Yeni, S., et al. 2022. Andrologia. 54: e14494. PMID: 35676072
- Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. | Pofi, R., et al. 2022. Sci Transl Med. 14: eabl8503. PMID: 35704597
- Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. | AbdelRazek, M., et al. 2022. World J Urol. 40: 2063-2070. PMID: 35773357
Inhibitor of:
δ-sarcoglycan, C22orf13, Carboxylesterase (CES), cGKI alpha, Dexras2, Eppin, FIZ1, GCS-β-1, Guanylate Cyclase (GUCA), MOXD1, PDE11A, PDE5A, PDE6, PDE6Aα, PDE6G, PDE6H, PP5, rat endothelium, RD3L, Relaxin 1, RPGR, Semenogelin-1, Smooth muscle cells, TBX4, TEF-5, and VAP-1.Activator of:
α-sarcoglycan, 2′-PDE, 4930458L03Rik, A330050F15Rik, ABCE1, ARA54, Arbp, ATP6E, BC031181, blue-sensitive opsin, Brn-3c, c-GMP, C11orf20, C14orf145, C22orf13, C5orf23, cAMP-GEFII, CCK-AR, CCT8L1, cGKI, cGKI α, cGKII, Chromozym PK, CNG-β3, CNG-2, Cngb1, CRISP-2, dystrophin, FSCB, FSIP1, GCAP2, GCS-α-3, GUCD1, Gucy2d, Gucy2g, HMW-Guanylin, kallistatin, MCH-2R, MG50, MNS1, MRP-L32, MSG1, neuroguidin, NPR-C, nyctalopin, Olfr392, OPN1MW2, OR10AD1, OR10P1, OR12D2, OR2A4, OR2B3, OR2H1, OR2J2, OR2W1, OR4D6, OR4K5, OR4M1, OR6K2, OR8K1, PAPD1, PATE3, Pate4, PDE10A, PDE1C, PDE5A, PDE6α, PDE8A, PKAα cat, PPEF-1, PR48, Psf1, RAPGEF5, rcRPE, Relaxin Receptor 3, RGS11, RGS9, Rim2, ROS-GC2, RP1, sGC α1, sGC α2, sGC β1, sGC β2, SPAG1, StARD8, Synaptoporin, t-GMP, TMEM150B, TMEM25, and UNC-13.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tadalafil, 50 mg | sc-208412 | 50 mg | $176.00 |